Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
RESEARCH TOOLSreports
Holding ABOS?
Track your performance easily
ABOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.08 - $5.09
Previous Close$2.37
Volume179.87K
Average Volume (3M)191.47K
Market Cap
$142.39M
Enterprise Value-$27.97M
Total Cash (Recent Filing)$200.34M
Total Debt (Recent Filing)$29.99M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Mar 31, 2025EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding60,079,778
10 Day Avg. Volume219,583
30 Day Avg. Volume191,472
Standard Deviation0.29
R-Squared0.00004
Alpha-0.00385
Financial Highlights & Ratios
Price to Book (P/B)0.66
Price to Sales (P/S)28718.13
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.59K
Enterprise Value/Gross Profit-5.59K
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$12.00Price Target Upside408.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Acumen Pharmaceuticals News
PremiumCompany Announcements
Acumen Pharmaceuticals Advances Alzheimer’s Therapeutic
PremiumCompany Announcements
Acumen Pharma Reports Q3 2024, Highlights Alzheimer’s Focus
Ownership Overview
27.10% Insiders
11.49% Mutual Funds
42.23% Other Institutional Investors
13.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $2.08 and its highest was $5.09 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Currently, no data Available
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Mar 31, 2025 which is in 125 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.138.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -$0.49.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,079,777 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -16.77%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Among the largest hedge funds holding Acumen Pharmaceuticals’s share is RA Capital Management. It holds Acumen Pharmaceuticals’s shares valued at 37M.
---
Acumen Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (408.47% Upside)
$12.00 (408.47% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.42%
12-Months-Change
Fundamentals
Return on Equity
-32.83%
Trailing 12-Months
Asset Growth
-6.77%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
---
ABOS Company Deck
---
ABOS Earnings Call
Q3 2024
0:00 / 0:00
---
ABOS Stock 12 Month Forecast
Average Price Target
$12.00
▲(408.47% Upside)
Technical Analysis
Best Analysts Covering ABOS
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-30.06%
reiterated a buy rating 14 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -30.06% per trade.
---